FDA Approves SYMVESS To Treat Extremity Vascular Trauma
(RTTNews) - Humacyte, Inc. (HUMA), Friday said that the Food and Drug Administration or FDA has granted approval for SYMVESS for use in adults as a vascular conduit for extremity arterial injury.
Humacyte's Biologics License Application (BLA) included positive results from the V005 pivotal Phase 2/3 study, as well as real-world evidence from the treatment of wartime injuries in Ukraine under a humanitarian aid program.
In clinical testing SYMVESS was observed to have high rates of patency, or blood flow, and low rates of amputation and infection.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.